Skip to main content
. 2022 Jun 14;66(7):e00308-22. doi: 10.1128/aac.00308-22

FIG 2.

FIG 2

Clinical efficacy of CAMB in patients with azole-resistant chronic mucocutaneous candidiasis (CMC). (a) Shown are the clinical severity scores for corresponding manifestations of CMC at baseline and during CAMB treatment, at the primary endpoint evaluation. (b) Evolution of clinical score over time following initiation of CAMB treatment.